Cellular mechanisms by which proinsulin C-peptide prevents insulin-induced neointima formation in human saphenous vein

R. S. Mughal · J. L. Scragg · P. Lister · P. Warburton · K. Riches · D. J. O’Regan · S. G. Ball · N. A. Turner · K. E. Porter

Received: 5 February 2010 / Accepted: 25 February 2010 / Published online: 12 May 2010 © The Author(s) 2010. This article is published with open access at Springerlink.com

Abstract

Aims/hypothesis Endothelial cells (ECs) and smooth muscle cells (SMCs) play key roles in the development of intimal hyperplasia in saphenous vein (SV) bypass grafts. In diabetic patients, insulin administration controls hyperglycaemia but cardiovascular complications remain. Insulin is synthesised as a pro-peptide, from which C-peptide is cleaved and released into the circulation with insulin; exogenous insulin lacks C-peptide. Here we investigate modulation of human SV neointima formation and SV-EC and SV-SMC function by insulin and C-peptide.

Methods Effects of insulin and C-peptide on neointima formation (organ cultures), EC and SMC proliferation (cell counting), EC migration (scratch wound), SMC migration (Boyden chamber) and signalling (immunoblotting) were examined. A real-time RT–PCR array identified insulin-responsive genes, and results were confirmed by real-time RT-PCR. Targeted gene silencing (siRNA) was used to assess functional relevance.

Results Insulin (100 nmol/l) augmented SV neointimal thickening (70% increase, 14 days), SMC proliferation (55% increase, 7 days) and migration (150% increase, 6 h); effects were abrogated by 10 nmol/l C-peptide. C-peptide did not affect insulin-induced Akt or extracellular signal-regulated kinase signalling (15 min), but array data and gene silencing implicated sterol regulatory element binding transcription factor 1 (SREBF1). Insulin (1–100 nmol/l) did not modify EC proliferation or migration, whereas 10 nmol/l C-peptide stimulated EC proliferation by 40% (5 days).

Conclusions/interpretation Our data support a causative role for insulin in human SV neointima formation with a novel counter-regulatory effect of proinsulin C-peptide. Thus, C-peptide can limit the detrimental effects of insulin on SMC function. Co-supplementing insulin therapy with C-peptide could improve therapy in insulin-treated patients.

Keywords C-peptide · Endothelial cell · Human · Insulin · Migration · Neointima · Proliferation · Saphenous vein · Signalling · Smooth muscle cell · Sterol regulatory element binding transcription factor 1

Abbreviations

EC Endothelial cell
ERK Extracellular signal-regulated kinase
HPRT1 Hypoxanthine phosphoribosyltransferase 1
IGF1R IGF 1 receptor
IMA Internal mammary artery
PI3K Phosphoinositide 3-kinase
SMC Smooth muscle cell
SORBS1 Sorbin and SH3 domain containing protein 1
SREBF1  Sterol regulatory element binding transcription factor 1
SV  Saphenous vein

Introduction

Adults with diabetes have an increased prevalence of coronary heart disease compared with non-diabetic individuals [1–4]. Intensive control of hyperglycaemia retards diabetic microvascular complications (e.g. retinopathy, nephropathy and neuropathy) [5], but beneficial macrovascular effects (coronary atherosclerosis) are less apparent [6]. Long-term outcomes of revascularisation are disappointing, irrespective of the mode: angioplasty, stenting or coronary artery bypass grafting [1, 7, 8].

The autologous saphenous vein (SV) is used routinely as a conduit for coronary artery bypass grafts. Occlusions caused by intimal hyperplasia are common [9–11], with only ~50% of grafts patent after 10 years and fewer in diabetic patients [12]. Implantation of the SV graft immediately exposes it to arterial pressure, with profound effects on endothelial cell (EC) and smooth muscle cell (SMC) biology. Loss of homeostatic regulation due to EC damage promotes SMC proliferation and migration in the graft wall, culminating in intimal hyperplasia and graft occlusion [13].

Insulin effectively controls blood glucose but can itself stimulate SMC proliferation and migration [14], increasing neointima formation in balloon-injured arteries of normal and diabetic rats [15–17]. Insulin also reportedly enhanced neointima formation in organ-cultured SV in tissue from five patients [18]. Insulin acting on SV-SMCs may therefore contribute to the pathogenesis of intimal hyperplasia in insulin-dependent diabetic patients.

Human proinsulin C-peptide is a 31-amino-acid peptide that links the A and B chains of proinsulin, ensuring its correct folding [19–21]. C-peptide is cleaved from proinsulin and released into the circulation with insulin in equimolar concentrations. Early studies reported no biological function of C-peptide [22], an observation supported by lack of interspecies conservation of the C-peptide sequence, both in chain length and amino acid composition. However, it is now apparent that human proinsulin C-peptide is biologically active and modulates cellular function [20]. Type 1 diabetic patients receive insulin therapy from an early stage, and the majority of type 2 patients over time also require insulin. Exogenously administered insulin does not contain C-peptide. Low sustained concentrations of C-peptide are beneficial [23–25], and chronic administration of replacement C-peptide with insulin ameliorates microvascular complications in animal models and type 1 diabetic patients [19, 20, 26]. A combination of insulin and C-peptide may therefore provide a more effective treatment for diabetic patients than insulin alone.

Here we explored the interplay between human insulin and proinsulin C-peptide on intimal hyperplasia in organ-cultured SVs from patients without diabetes and on the two key cell types involved in neointima formation, ECs and SMCs, to resolve their independent and joint cell-type-specific effects.

Methods

Materials Cell culture reagents were purchased from Invitrogen (Paisley, UK), except FBS from LabTech International (Ringmer, UK). Proinsulin C-peptide, insulin and PDGF-BB were from Sigma (Poole, UK). PD98059 and LY294002 were from Calbiochem (Nottingham, UK). Migration assay chambers were from BD Biosciences (Oxford, UK).

Tissue and cell culture Samples of SV and internal mammary artery (IMA) were obtained from non-diabetic patients undergoing elective coronary artery bypass grafting at the Leeds General Infirmary, with local ethical committee approval and informed patient consent. The study was carried out in accordance with the principles of the Declaration of Helsinki as revised in 2000. Organ cultures were performed using undistended SV as we have described previously [27] in the absence or presence of insulin, alone or with C-peptide. Segments were fixed and processed to 10 μm. Neointimal thickness was determined using computational analysis on high field magnification at 60 μm intervals along each section by two independent observers.

SMCs were cultured from human SV, IMA and aortic root by an explant technique as we have described previously [28]. SMCs were maintained at 37°C in DMEM containing 25 mmol/l glucose and 10% FBS in a humidified atmosphere of 5% CO2 in air. SV-ECs were harvested by collagenase digestion and cultured as described previously [29]. Experiments were performed on cells of passage number 2–6 from different patients.

Proliferation assays SV-EC proliferation assays were performed by seeding cells from different patients in 24-well culture plates at a density of 10,000 per well in full endothelial growth medium (20% FBS). After 30–32 h incubation cells were quiesced in medium containing 1% FBS for 16 h. Cells were then exposed to control growth medium (1% or 10% FBS as appropriate) and selected concentrations of insulin, C-peptide or in combination.
Medium and drugs were replaced on days 2 and 4 and viable cell number determined in triplicate wells on day 5 using Trypan Blue and a haemocytometer.

SV-SMC and IMA-SMC proliferation assays were performed essentially as described previously [28]. After plating (10,000 cells per well), cells were incubated overnight in full growth medium, then quiesced in serum-free medium for 3 days before transfer to control growth medium (DMEM with 0.2% FBS and 10 ng/ml platelet-derived growth factor) alone or with appropriate supplements (insulin and/or C-peptide). Medium and drugs were replaced on days 2 and 4 and viable cell number determined in triplicate wells on the appropriate day (usually day 7).

Migration assays SV-EC migration was investigated in six- well plates using a modification of a ‘scratch wound’ method [30]. Briefly, duplicate scratches were made with a sterile 1 ml pipette tip in confluent endothelial monolayers, reference points etched in the dishes and images were captured (0 h). Cells were then exposed to the relevant media with appropriate stimuli in a tissue-culture incubator for an additional 24 h. Further images were then captured by aligning the dishes with the reference point made at time 0 h, and a second image acquired. Distances of each scratch closure were determined by measuring the cell-denuded area at equal intervals along the wound at each image time point for each treatment condition.

SV-SMC migration was studied using a modified Boyden chamber technique, as we have described previously [28]. Cells (100,000) from different patients were loaded in the upper chamber in medium supplemented with 0.4% FBS. The lower chamber contained 0.4% FBS with appropriate supplements (insulin and/or C-peptide). After incubation for 6 h at 37°C in a tissue-culture incubator, duplicate membranes were processed and evaluated by counting migrated cells on the underside of the membrane in 10 random fields under high power (×400) light microscopy [28].

Immunoblotting Serum-starved cells were exposed to serum-free medium containing insulin and/or C-peptide for 15 min before preparing whole cell homogenates and immunoblotting as described previously [31]. Phosphorylation of Akt (Ser473) and extracellular signal-regulated kinase (ERK) (Thr202/Tyr204) was determined using phospho-specific and expression antibodies (Cell Signaling Technology, Hitchin, UK). Immunolabelled bands were visualised by chemiluminescence and densitometric analysis performed as previously described [32].

PCR arrays Serum-deprived SV-SMCs were exposed to 0.4% FBS alone or supplemented with 100 nmol/l insulin for 6 h before extracting RNA and performing first-strand cDNA synthesis [33]. The cDNA was confirmed to be of suitable quality for array analysis using the SuperArray QC PCR array (SAbiosciences) and the ABI 7500 Real-Time PCR System. Samples of cDNA were then analysed using the Insulin Signalling Pathway Array (SAbiosciences). Cycle threshold (\(C_t\)) values were obtained using Sequence Detection Software SDS v1.2.3 (Applied Biosystems) and data analysed by comparing \(C_t\) values of 84 insulin pathway genes with those of five different housekeeping genes using the SuperArray PCR array analysis software (SAbiosciences).

Real-time PCR Real-time RT-PCR performed as described previously [33] using the ABI 7500 Real-Time PCR System with the following human Taqman primer/probe sets: sterol regulatory element binding transcription factor 1 (SREBF1) (product number Hs01088691_m1), IGF 1 receptor (IGF1R) (Hs00541255_s1), sorbin and SH3 domain containing protein 1 (SORBS1) (Hs00908953_m1) and GLUT4 (Hs00168966_m1). Data were expressed as a percentage of hypoxanthine phosphoribosyltransferase 1 (HPRT1) mRNA levels (Hs99999909_m1 primers) using the formula \(2^{-\Delta C_t} \times 100\), or normalised to control sample using the formula \(2^{-\Delta\Delta C_t}\).

SREBF1 gene silencing SV-SMCs were transfected with a combination of four different SREBF1-targeted siRNA oligonucleotides (100 nmol/l) (SMARTPool; Dharmacon, Cramlington, UK) using Lipofectamine 2000 transfection reagent (Invitrogen), as described previously [34]. Control cells were transfected in the absence of siRNA (mock transfected). Effects on protein levels were determined by immunoblotting with mouse monoclonal anti-SREBF1 antibody (ab3259, Abcam), using the method described above. The effects of SREBF1 gene silencing on SV-SMC migration were determined 36 h after transfection.

Statistical analysis All data are expressed as means ± SEM, with \(n\) representing the number of experiments on cells/tissue from different patients. Data were analysed as ratios using repeated measures one-way ANOVA with the Newman–Keuls post hoc test, using GraphPad Prism software (www.graphpad.com). \(p<0.05\) was considered statistically significant.

Results

Neointimal thickening in organ-cultured human SV The ability of insulin to modulate neointima formation was investigated using organ-cultured human SV from ten different patients (Fig. 1). Mean neointima thickness was 10.4±1.4 µm (median 11.7 µm, range 5.2–16.6 µm) after 14 days’ incubation and increased by 70% (\(p<0.01\))
following supplementation with 100 nmol/l insulin (mean 17.7±2.6 µm, median 16.7 µm, range 6.5–31.4 µm). Treatment of SV cultures with C-peptide (10 nmol/l) together with insulin (100 nmol/l) prevented the increase in neointima (mean 8.8±1.36 µm, median 8.9 µm, range 4.8–15.5 µm).

Proliferation and migration of ECs promote re-endothelialisation of the damaged vessel wall, thereby limiting neointimal development. By contrast, SMC proliferation and migration contribute to neointimal development. We therefore investigated the effects of insulin and C-peptide on SV-EC and SV-SMC proliferation and migration.

**Endothelial cell proliferation** Figure 2a shows SV-EC counts from ten different patients cultured in 10% FBS with no change in cell number in response to 1–100 nmol/l insulin after 5 days. Similarly, no effect of insulin was seen in cells exposed to 1% FBS (data not shown). When cells were exposed to C-peptide (10 nmol/l) alone, a significant increase in cell number of ~40% was observed, which was not affected by insulin (Fig. 2b). Further studies revealed that C-peptide increased SV-EC proliferation at concentrations as low as 0.1 nmol/l (Fig. 2c).

**Endothelial cell migration** In the scratch wound assay, SV-ECs at the wound edge migrate to repopulate a denuded area created by the scratch (Fig. 2d). Cells exposed to 1% FBS (Fig. 2e) had half the migratory capacity of cells in 10% FBS (Fig. 2f). No modulatory effects were observed with either insulin, C-peptide or both together in either 1% or 10% FBS-supplemented media (Fig. 2e, f).

**Smooth muscle cell proliferation** SV-SMCs from four different patients cultured in control growth medium exhibited a 2.5-fold increase in cell number after 7 days compared with day 0 (Fig. 3a). C-peptide did not affect cell number observed in the absence of insulin, but supplementation with 10–100 nmol/l insulin further increased SV-SMC proliferation in a concentration-dependent manner (ANOVA p<0.0001), with 100 nmol/l insulin stimulating a 55% increase in cell number (Fig. 3a). These mitogenic effects of insulin were prevented by co-incubation with 10 nmol/l C-peptide (Fig. 3a). The mean number of detached cells observed throughout the proliferation assays was <1% of the total and was unaffected by any treatment (data not shown).

IMA-SMCs cultured from the same four patients as the SV-SMCs, displayed a 2.1-fold increase in cell number after 7 days treatment in control growth medium (Fig. 3b), which was lower than that observed for SV-SMCs. In stark contrast to SV-SMCs, insulin (10–100 nmol/l) had no effect on IMA-SMC proliferation, and C-peptide (10 nmol/l) did not modulate proliferation in the presence or absence of insulin (Fig. 3b).

A time course of the effects of insulin and C-peptide on SV-SMC proliferation revealed that the mitogenic effects of insulin, and the attenuating effects of C-peptide, were evident over a 3–7 day period (Fig. 3c). Comparison of areas under the proliferation curves revealed that cells exposed to insulin proliferated at a higher rate than control cells (p<0.01) or cells cultured in the presence of both insulin plus C-peptide (p<0.05). There was no difference in proliferation rates between control cells and those cultured with insulin plus C-peptide. Further studies revealed that C-peptide attenuated insulin-induced SV-SMC proliferation at concentrations as low as 0.1 nmol/l (Fig. 3d). In contrast to C-peptide, a scrambled version of C-peptide (31-mer with the same amino acid content as C-peptide but in a random order) had no effect on proliferation of SV-SMCs in the absence or presence of insulin (Fig. 3e).

In view of C-peptide’s lack of effect on arterial vs venous SMCs, and a previous report that it increased aortic SMC proliferation in the absence of insulin [35], we investigated the effects of insulin and C-peptide on SMCs cultured from
human aortic root (Fig. 3f). C-peptide increased proliferation of human aortic SMCs (35% increase) in agreement with Walcher et al. [35]. Insulin alone also stimulated a 28% increase in aortic SMC number. Insulin and C-peptide together showed no additive proliferative response compared with either agent alone (Fig. 3f), and scrambled C-peptide had no effect (data not shown).

Smooth muscle cell migration SMC migration was assessed using Boyden chambers. A significant increase (2.5-fold) was observed in migration towards a 100 nmol/l insulin stimulus (Fig. 4a). Consistent with C-peptide’s effects on neointima formation and SV-SMC proliferation (Figs 1, 3), inclusion of 10 nmol/l C-peptide with insulin fully prevented insulin-induced migration of SV-SMCs (Fig. 4a, n=11 patients). Pre-treatment with inhibitors of the ERK pathway (PD98059) or phosphoinositide 3-kinase (PI3K)/Akt pathway (LY294002) fully prevented insulin-induced migration (Fig. 4b), indicating essential roles for these signalling pathways.

Smooth muscle cell signalling We next investigated whether C-peptide could be acting by inhibiting the ERK or PI3K/Akt pathways, the two major pathways that lie downstream of the insulin receptor. Insulin stimulated phosphorylation of Akt (Fig. 4c), but ERK phosphorylation was not markedly increased, probably owing to the high basal level of ERK activation in these cells (Fig. 4d). C-peptide alone or in combination with insulin did not modulate Akt or ERK signalling (Fig. 4c,d). Thus, C-peptide ablates the effects of insulin on SV-SMC function independently of ERK or Akt signalling pathways.

Smooth muscle cell gene expression To identify insulin-responsive genes modulated by C-peptide, we used a SYBR-Green-based real-time RT–PCR array to monitor expression of 84 genes involved in insulin signalling, including insulin-receptor-associated proteins, components of the ERK and Akt pathways, insulin-responsive genes, transcription factors and genes involved in carbohydrate and lipid metabolism. SV-SMCs from six patients were
treated with or without 100 nmol/l insulin for 6 h before extracting RNA. Concomitant migration assays were performed to confirm the functional effects of insulin and C-peptide on SV-SMC migration (Fig. 5a).

Data are presented in Fig. 5b as a volcano plot with full data included in the Electronic supplementary material (ESM) Table 1. We selected four genes for further study based on changes in transcript levels and reproducibility (statistical significance): namely IGF1R, SORBS1, GLUT4 and SREBF1.

Tagman primer/probe sets were utilised to confirm array data using the same RNA samples. The insulin-induced increase in SREBF1 mRNA expression and decrease in IGFI R mRNA expression were confirmed by RT–PCR (Fig. 5c,d). However, the array data could not be confirmed for SORBS1 or GLUT4 (data not shown).

Insulin-induced SREBF1 mRNA expression was fully prevented by co-incubation with C-peptide (Fig. 5c). By contrast, the effect of insulin on IGFI R expression was not modulated by C-peptide (Fig. 5d). The acute temporal profiles of SREBF1 and IGF1R mRNA expression in response to insulin, with or without C-peptide, were then determined over the 6 h period (Fig. 5e,f). Insulin-induced SREBF1 mRNA expression was evident after 3 h and rose thereafter, reaching a 40% increase after 6 h (ANOVA, p < 0.01) (Fig. 5e). No increase in SREBF1 mRNA levels was apparent when C-peptide was present with insulin (ANOVA, p = 0.713) (Fig. 5e). In contrast to SREBF1, the insulin-induced decrease in IGF1R mRNA expression after 2–6 h (ANOVA, p < 0.05) was not modulated by C-peptide (Fig. 5f).

Effect of SREBF1 gene silencing on SV-SMC migration

The above data implicated SREBF1 as a molecular target for the antagonistic effects of C-peptide on insulin-induced SV-SMC proliferation and migration. To confirm that SREBF1 expression was involved in insulin-induced SV-SMC migration, we employed a gene-silencing approach.
The principal finding of our study was that neointima formation in organ-cultured human SVs was increased in the presence of insulin, an effect abrogated by proinsulin C-peptide. Neointima formation requires SMC migration and proliferation, both of which were induced by insulin and fully inhibited by C-peptide. The effects of C-peptide were not a result of inhibition of insulin-mediated Akt and ERK signalling, but were related to reduced insulin-induced SREBF1 expression.

In agreement with earlier studies [15, 18] we revealed a causative role for insulin in neointima formation but importantly demonstrated a counter-regulatory effect of C-peptide. Our model mimics the situation of insulin-treated diabetes, with the presence of insulin but not C-peptide, and suggests that co-supplementing insulin with C-peptide could provide a better treatment than insulin alone.

Damage to the SVs during harvesting and implantation inevitably induces endothelial dysfunction, a feature associated with neointima formation. As effective re-endothelialisation is known to inhibit neointimal hyperplasia [36], we investigated whether insulin and/or C-peptide could modulate EC migration and/or proliferation. Insulin did not alter EC proliferation, whereas C-peptide induced an increase, an effect maintained in the presence of insulin. Migration was not affected by either insulin or C-peptide. Thus, C-peptide acts directly on SMCs to prevent neointima formation while increasing EC proliferation to promote re-endothelialisation [36].

In agreement with a previous study [37], insulin increased migration of SV-SMCs via ERK and PI3K/Akt pathways. However, C-peptide’s counter-regulation was not due to inhibition of these pathways. The mode of action of C-peptide is unknown, although it binds to human cell membranes [38] and its target may be a G-protein-coupled receptor in some tissues [39]. C-peptide has been shown to internalise in Swiss 3T3 and HEK 293 cells [40], and a very recent study in human aortic ECs and umbilical artery SMCs indicated that C-peptide was internalised by early endosomes [41]. Whether the endosomal pathway is functional in human SV-SMCs and required for C-peptide trafficking will require elucidation in future studies. Importantly, our data do not support speculation that C-peptide binds to the insulin receptor [42]. Thus, in human SV-SMCs, C-peptide acts independently of the insulin receptor and its immediate downstream signalling pathways.

Insulin increased SV-SMC proliferation in a concentration-dependent manner. C-peptide even at very low concentration abolished these effects, consistent with its activity at nanomolar concentrations found in plasma [43] and full saturation of C-peptide binding sites at low nanomolar concentrations [38].

In the vasculature, the reported effects of C-peptide are at variance and potentially explained by different experimental approaches. Two previous studies have claimed that C-peptide reduces SMC proliferation. One report used rat
SMCs and human C-peptide and saw a modest effect on high glucose-induced (25 mmol/l) proliferation, but only after 3 weeks [44]. A more recent study using human arterial SMCs also observed increased proliferation with high glucose culture that was attenuated by C-peptide [45]. By contrast, our data differ from those reporting a mitogenic effect of C-peptide on human and rat aortic SMCs [35], in which C-peptide was coupled to activation of PI3K/Akt and ERK pathways, which were not modulated by C-peptide in our study using SV-SMCs. This raises the intriguing possibility that C-peptide has opposing effects on SMCs from different vascular beds. To test this, we cultured human aortic SMCs and found that C-peptide was pro-proliferative, in agreement with the findings of Walcher et al. [35]. However, when aortic SMCs were cultured in the presence of insulin, itself a mitogen, no additive effect of C-peptide was observed. Unlike our present study, in none of the above studies was the effect of insulin investigated. It is also important to note that in individuals without diabetes C-peptide is only ever present with insulin. The findings of all these reports can therefore be reconciled by taking into account species and source of SMCs, together with insulin, C-peptide and glucose concentrations.
In contrast to the SVs, IMA grafts provide better long-term patency even in diabetic patients [46], indicating resistance to restenosis. This remarkable difference in patency between conduits is clearly multifactorial, but we have previously shown that SV-SMCs are inherently more proliferative than IMA-SMCs from the same patients [32]. In direct contrast to SV cells, insulin did not promote IMA-SMC proliferation, which may help explain the similar patency rates of IMA grafts in insulin-treated patients compared with those in non-diabetic patients [46]. The inability of insulin to induce IMA-SMC proliferation was not due to lack of insulin signalling, as both Akt and ERK phosphorylation were evident in insulin-treated IMA-SMCs (data not shown). These data highlight the importance of using relevant cell types and add to the concept of cell-type-specific effects of both insulin and C-peptide.

Having established the effects of insulin and C-peptide on SV-SMC migration and proliferation, we used an insulin signalling array to identify potential molecular mechanisms. SREBF1 mRNA expression was increased in response to insulin; an effect attenuated by C-peptide. SREBF1 gene silencing selectively attenuated the insulin-induced component of SV-SMC migration, strongly suggesting that the ability of C-peptide to reduce SV-SMC migration is due to inhibition of insulin-induced SREBF1 expression. SREBF1 (SREBP1) is a member of the basic helix-loop-helix-leucine zipper (bHLH-Zip) family of transcription factors that regulate lipid and carbohydrate metabolism [47]. A role for SREBF1 in proliferation of murine aortic SMCs is reported [48]. SREBF1, by regulating lipid and cholesterol biosynthesis, may play a role in plasma membrane synthesis and could optimise membrane properties for SV-SMC migration and proliferation in response to insulin. Importantly, these effects of insulin can be abrogated by C-peptide.

Vascular SMC proliferation is induced by a plethora of growth factors and cytokines, and additionally hyperinsulinaemia has been implicated as an important risk factor for atherosclerotic lesion formation in diabetic patients through increased SMC proliferation [49]. Here we have shown that insulin and its C-peptide differ in their effects on cells from different vascular beds. These peptides are normally secreted in equimolar amounts but this relationship is perturbed when exogenous, recombinant insulin is administered to replace natural synthesis.

A potential limitation of our study was the use of 100 nmol/l insulin: a supraphysiological concentration when compared with that observed in vivo after a meal in normal (−0.3−0.4 nmol/l) or insulin-resistant (−1.4−1.5 nmol/l) individuals. Relatively high concentrations of insulin are often required in vitro to observe functional effects, probably reflecting the numerous differences between in-vitro functional assays and the situation in vivo. Lower concentrations of insulin (e.g. 25 nmol/l) also resulted in increased SV-SMC proliferation in our experiments (Fig. 3a), but we selected the 100 nmol/l concentration based on the reproducibility and magnitude of its effects. One strength of our study was the use of cells from multiple patients. Interestingly, C-peptide had maximal effects on SV-EC and SV-SMC proliferation at concentrations as low as 0.1 nmol/l (Figs 2c, 3d); levels of C-peptide that are physiologically relevant.

During the last decade there has been a wealth of new information regarding the impact of C-peptide on a variety of cell types and specific cell functions. However, until recently the major focus has been on the microvascular complications of type 1 diabetes [50], with its effects in type 2 diabetes being less well explored. It is generally perceived that C-peptide is beneficial (for reviews see [51, 52]), although the mechanisms underlying such effects appear to be tissue- and cell-type specific, and insulin is not always necessary for C-peptide to function. Indeed, our own data, for example, indicate a differential effect of C-peptide on SMCs from aorta and SV. In this respect, elucidation of the specific mechanisms underlying the functional effects of C-peptide in relevant cell types is of key importance.

In summary, our study is the first to report a direct modulatory effect of proinsulin C-peptide on the potentially deleterious effects of insulin on human SV neointima.
formation, through effects on both SMC and EC function. Our data implicate SREBF1 as a candidate for further investigation. Co-administration of C-peptide with insulin may improve SV bypass graft patency rates in insulin-treated diabetic patients. Clinical trials will be necessary to test this hypothesis.

Acknowledgements We gratefully acknowledge funding from The British Heart Foundation and the University of Leeds, UK. S.G. Ball is a British Heart Foundation Professor of Cardiology. N.A. Turner is the recipient of a Research Councils UK Academic Fellowship. We are grateful to J. Kaye and C. Bauer for cell culture expertise.

Duality of interest The authors declare that there is no duality of interest associated with this manuscript.

Open Access This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

References

1. Hakala T, Pitkanen O, Halonen P, Mustonen J, Turpeinen A, Hippelainen M (2005) Early and late outcome after coronary artery bypass surgery in diabetic patients. Scand Cardiovasc J 39:177–181
2. Ledru F, Ducimetiere P, Battaglia S et al (2001) New diagnostic criteria for diabetes and coronary artery disease: insights from an angiographic study. J Am Coll Cardiol 37:1543–1550
3. Herlitz J, Brandrup-Wognsen G, Caidahl K et al (1997) Mortality and morbidity among patients who underwent combined valve and coronary artery bypass surgery: early and late results. Eur J Cardiothorac Surg 12:836–846
4. Stone PH, Muller JE, Hartwell T et al (1989) The effect of diabetes mellitus on prognosis and serial left ventricular function after acute myocardial infarction: contribution of both coronary disease and diastolic left ventricular dysfunction to the adverse prognosis. The MILIS Study Group. J Am Coll Cardiol 14:49–57
5. Nathan DM, Cleary PA, Backlund JY et al (2005) Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 353:2643–2653
6. Duckworth W, Abraira C, Morizt T et al (2009) Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 360:129–139
7. Cutlip DE, Chauhan MS, Baim DS et al (2002) Clinical restenosis after coronary stenting: perspectives from multicenter clinical trials. J Am Coll Cardiol 40:2082–2089
8. Kornowski R, Mintz GS, Kent KM et al (1997) Increased restenosis in diabetes mellitus after coronary interventions is due to exaggerated intimal hyperplasia. A serial intravascular ultrasound study. Circulation 95:1366–1369
9. Gitman MR, Okrainec K, Nguyen H et al (2005) Impact of diabetes on 12-month outcomes following coronary artery bypass graft surgery: results from the ROSETTA–CABG Registry. Can J Cardiol 21:1169–1174
10. Lorusso R, Pentiirici S, Raddino R et al (2003) Influence of type 2 diabetes on functional and structural properties of coronary artery bypass conduits. Diabetes 52:2814–2820
11. Thourani VH, Weintraub WS, Stein B et al (1999) Influence of diabetes mellitus on early and late outcome after coronary artery bypass grafting. Ann Thorac Surg 67:1045–1052
32. Turner NA, Ho S, Warburton P, O’Regan DJ, Porter KE (2007) Smooth muscle cells cultured from human saphenous vein exhibit increased proliferation, invasion, and mitogen-activated protein kinase activation in vitro compared with paired internal mammary artery cells. J Vasc Surg 45:1022–1028

33. Turner NA, Mughal RS, Warburton P, O’Regan DJ, Ball SG, Porter KE (2007) Mechanism of TNFα-induced IL-1α, IL-1β and IL-6 expression in human cardiac fibroblasts: effects of statins and thiazolidinediones. Cardiovasc Res 76:81–90

34. Turner NA, Hall KT, Ball SG, Porter KE (2007) Selective gene silencing of either MMP-2 or MMP-9 inhibits invasion of human saphenous vein smooth muscle cells. Atherosclerosis 193:36–43

35. Walcher D, Babiak C, Polteck P et al (2006) C-Peptide induces vascular smooth muscle cell proliferation: involvement of SRC-kinase, phosphatidylinositol 3-kinase, and extracellular signal-regulated kinase 1/2. Circ Res 99:1181–1187

36. Tanous D, Brasen JH, Choy K et al (2006) Probucol inhibits in-stent thrombosis and neointimal hyperplasia by promoting re-endothelialization. Atherosclerosis 189:342–349

37. Wang CC, Gurevich I, Draznin B (2003) Insulin affects vascular smooth muscle cell phenotype and migration via distinct signaling pathways. Diabetes 52:2562–2569

38. Rigler R, Pramanik A, Jonasson P et al (1999) Specific binding of proinsulin C-peptide to human cell membranes. Proc Natl Acad Sci U S A 96:13318–13323

39. Al Rasheed NM, Meakin F, Royal EL et al (2004) Potent activation of multiple signalling pathways by C-peptide in opossum kidney proximal tubular cells. Diabetologia 47:987–997

40. Lindahl E, Nyman U, Melles E et al (2007) Cellular internalization of proinsulin C-peptide. Cell Mol Life Sci 64:479–486

41. Luppi P, Geng X, Cifarelli V, Drain P, Trucco M (2009) C-peptide is internalised in human endothelial and vascular smooth muscle cells via early endosomes. Diabetologia 52:2218–2228

42. Grunberger G, Qiang X, Li Z et al (2001) Molecular basis for the insulinomimetic effects of C-peptide. Diabetologia 44:1247–1257

43. Wahren J, Ekberg K, Johansson J et al (2000) Role of C-peptide in human physiology. Am J Physiol Endocrinol Metab 278:E759–E768

44. Kobayashi Y, Naruse K, Hamada Y et al (2005) Human proinsulin C-peptide prevents proliferation of rat aortic smooth muscle cells cultured in high-glucose conditions. Diabetologia 48:2396–2401

45. Cifarelli V, Luppi P, Tse HM, He J, Piganelli J, Trucco M (2008) Human proinsulin C-peptide reduces high glucose-induced proliferation and NF-kappaB activation in vascular smooth muscle cells. Atherosclerosis 201:248–257

46. Influence of diabetes on 5-year mortality and morbidity in a randomized trial comparing CABG and PTCA in patients with multivessel disease: the Bypass Angioplasty Revascularization Investigation (BARI) (1997) Circulation 96:1761–1769

47. Raghow R, Yellaturu C, Deng X, Park EA, Elam MB (2008) SREBP1c: the crossroads of physiological and pathological lipid homeostasis. Trends Endocrinol Metab 19:65–73

48. Zhou RH, Pesant S, Cohn HI, Eckhart AD (2008) Enhanced sterol response element-binding protein in postintervention restenotic blood vessels plays an important role in vascular smooth muscle proliferation. Life Sci 82:174–181

49. Despres JP, Lamarche B, Mauriege P, Cantin B, Lupien PJ, Dagenais GR (1996) Risk factors for ischaemic heart disease: is it time to measure insulin? Eur Heart J 17:1453–1454

50. Wahren J, Sima AA (2009) C-peptide is relevant in type 1 diabetes and its complications: summary and conclusions to the special issue. Rev Diabet Stud 6:223–224

51. Hills CE, Brunskill NJ (2009) Cellular and physiological effects of C-peptide. Clin Sci (Lond) 116:565–574

52. Nordquist L, Wahren J (2009) C-Peptide: the missing link in diabetic nephropathy? Rev Diabet Stud 6:203–210